First conjugates based on a Sigma receptor modulator and a proteasome-impairing agent. Design, synthesis and exploratory biological evaluation in cancer cells.
Cancer cells rely on a finely tuned proteostasis network to cope with high metabolic and proliferative demands. Targeting this vulnerability through the simultaneous modulation of both Sigma receptors (SRs) subtypes (i.e. S1R and S2R) and proteasome function represents an attractive and unprecedented strategy for the d...